This symposium took place on 9th June 2016, as a part of the 21st Congress of the European Hematology Association (EHA) 2016 in Copenhagen, Denmark
Chairperson: Eva Kimby1
Speakers: Eva Kimby,1 Georg Lenz,2 Catherine Thieblemont,3 Pier Luigi Zinzani4
1. Hematology Center, Department of Internal Medicine, Karolinska Institute, Stockholm, Sweden
2. Universitätsklinikum Münster, Münster, Germany
3. Hôpital Saint-Louis, Paris, France
4. Institute of Haematology, “L. e. A. Seràgnoli”, University of Bologna, Bologna, Italy
Disclosure: Prof Kimby is on advisory boards for Celgene, Pharmacyclics, Janssen, Baxalta, Gilead, and AbbVie and has received research support from Roche and Pfizer. Prof Lenz: Gilead (advisory board, invited speaker), Janssen (advisory board, invited speaker, grant support), Celgene (advisory board, invited speaker, grant support), Roche (advisory board, invited speaker), NanoString (advisory board). Prof Thieblemont has been an expert advisory board member for Janssen, Roche, Celgene, Gilead, Bayer. Prof Zinzani has been a speaker for Celgene, Gilead, Takeda, BMS, Janssen. Has received Honoraria from Celgene, Gilead, BMS, Jannssen, Pfizer, TG Pharmaceuticals, Roche, BMS, Bayer and has served on advisory boards for Celgene, Gilead, BMS, Janssen, Pfizer, TG Pharmaceutical, Roche, and Takeda.
Acknowledgements: Writing assistance was provided by Dr Tim Ibbotson of ApotheCom.
Support: The publication of this article was funded by Celgene. The views and opinions expressed are those of the authors and not necessarily Celgene.
Citation: EMJ Hematol. 2016; 4:38-46.
A recent symposium at the European Hematology Association (EHA) congress, chaired by Prof Eva Kimby, explored the changing paradigms in the treatment of non-Hodgkin’s lymphoma (NHL) and the potential impact of new approaches to diagnosis and treatment. Prof Kimby opened the symposium by discussing the recent therapeutic advances in the treatment of follicular lymphoma (FL). Prof Georg Lenz then spoke about the clinical implications of diffuse large B cell lymphoma (DLBCL) diagnosis and the manner in which disease subtyping can foster effective use of targeted therapies. Prof Catherine Thieblemont presented on post-induction treatment in DLBCL, and the importance of effective treatment options to limit the number of patients who fail first-line therapy. Prof Pier Luigi Zinzani then concluded the symposium by presenting data on the new immuno-oncology treatments being evaluated in patients with relapsed or refractory NHL.